{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010752","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.083868+00:00","generated_at":"2026-06-17T09:18:18.101816+00:00","sec_items":["1.01","1.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptevo raises $9.6M non-dilutive by selling IXINITY payment rights to XOMA; repays debt","bullets":["Sold all future IXINITY deferred payments and a portion of milestones to XOMA for $9.6M closing payment.","Retains rights to up to $5.8M in additional milestones (Canadian, European, net sales) through 2035.","Used part of proceeds to fully repay and terminate MidCap credit agreement, becoming debt-free.","Pro forma cash ~$26M, extending runway beyond 12 months; additional $50K possible if Q1 2023 deferred payment exceeds $500K."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010752","json":"https://secwatch.observer/filing/0000950170-23-010752.json","markdown":"https://secwatch.observer/filing/0000950170-23-010752.md","text":"https://secwatch.observer/filing/0000950170-23-010752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023010752/0000950170-23-010752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023010752/apvo-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:18:18.101816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05fa42f3ca753154e063edd36d563732572524c0","claim":"Aptevo Therapeutics Inc. terminated Credit Agreement with MidCap Financial Trust with MidCap Financial Trust valued at Credit agreement terminated upon full repayment of all indebtedness (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, in connection with the closing of the Purchase Agreement, the Company repaid in full all indebtedness, liabilities and other obligations under, and terminated, that certain Credit Agreement by and between the Company and MidCap Financial Trust (\"MidCap\"), dated August 5, 2020 as amended from time to time.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023010752/0000950170-23-010752-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"MidCap Financial Trust"},{"label":"Value","value":"Credit agreement terminated upon full repayment of all indebtedness"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"},{"claim_id":"76568f81dde87e58b3885d75173f294598814de2","claim":"Aptevo Therapeutics Inc. entered into Payment Interest Purchase Agreement with XOMA (US) LLC valued at $9,600,000 at closing plus up to $50,000 post-closing (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, the Company entered into and closed a payment interest purchase agreement (the \"Purchase Agreement\") with XOMA (US) LLC (\"XOMA\") pursuant to which the Company sold to XOMA its right, title and interest in and to all of the Deferred Payments and a portion of the Milestone Payments.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023010752/0000950170-23-010752-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"XOMA (US) LLC"},{"label":"Value","value":"$9,600,000 at closing plus up to $50,000 post-closing"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}